Caroline Palomeque
Stock Analyst at Ladenburg Thalmann & Co.
(0.10)
# 4,660
Out of 4,835 analysts
175
Total ratings
30.4%
Success rate
-11.3%
Average return
Main Sectors:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Reiterated: Buy | $16 | $3.62 | +341.99% | 2 | Aug 10, 2026 | |
| ATHE Alterity Therapeutics | Initiated Coverage: Buy | $10 | $4.11 | +143.31% | 1 | Jun 16, 2026 | |
| HRMY Harmony Biosciences Holdings | Initiated Coverage: Buy | $59 → $54 | $41.10 | n/a | 2 | Oct 25, 2023 | |
| KRYS Krystal Biotech | Initiated Coverage: Buy | $154 | $345.55 | n/a | 2 | Oct 25, 2023 | |
| HALO Halozyme Therapeutics | Reiterated: Buy | $58 | $107.00 | n/a | 7 | Sep 11, 2023 | |
| ASND Ascendis Pharma | Reiterated: Buy | $166 | $261.23 | n/a | 12 | Sep 7, 2023 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $33 | $14.22 | n/a | 7 | Aug 16, 2023 | |
| ATAI AtaiBeckley | Reiterated: Buy | $11 | $7.35 | n/a | 6 | Aug 11, 2023 | |
| AVXL Anavex Life Sciences | Reiterated: Buy | $40 | $2.66 | n/a | 24 | Aug 9, 2023 | |
| DNLI Denali Therapeutics | Reiterated: Buy | $54 | $21.40 | n/a | 14 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $10.62 | n/a | 7 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 | $8.56 | n/a | 12 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $17.18 | n/a | 2 | Apr 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 | $2.97 | n/a | 5 | Apr 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.7051 | n/a | 8 | Apr 4, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $3.35 | n/a | 4 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $0.239 | n/a | 14 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.03 | n/a | 13 | Mar 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $4 → $40 | $6.57 | n/a | 11 | Mar 20, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 1,332p → 1,327p | 444p | n/a | 2 | Mar 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $34 | $0.3223 | n/a | 3 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $20 | $8.24 | n/a | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 | $2.10 | n/a | 6 | Mar 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $8 | $8.29 | n/a | 1 | Aug 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.00001 | n/a | 1 | Jun 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.006 | n/a | 1 | Jun 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $2.58 | n/a | 1 | May 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.075 | n/a | 1 | Apr 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $0.0003 | n/a | 1 | Mar 2, 2016 |
Ardelyx
Aug 10, 2026
Reiterated: Buy
Price Target: $16
Current: $3.62
Upside: +341.99%
Alterity Therapeutics
Jun 16, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $4.11
Upside: +143.31%
Harmony Biosciences Holdings
Oct 25, 2023
Initiated Coverage: Buy
Price Target: $59 → $54
Current: $41.10
Upside: n/a
Krystal Biotech
Oct 25, 2023
Initiated Coverage: Buy
Price Target: $154
Current: $345.55
Upside: n/a
Halozyme Therapeutics
Sep 11, 2023
Reiterated: Buy
Price Target: $58
Current: $107.00
Upside: n/a
Ascendis Pharma
Sep 7, 2023
Reiterated: Buy
Price Target: $166
Current: $261.23
Upside: n/a
COMPASS Pathways
Aug 16, 2023
Reiterated: Buy
Price Target: $33
Current: $14.22
Upside: n/a
AtaiBeckley
Aug 11, 2023
Reiterated: Buy
Price Target: $11
Current: $7.35
Upside: n/a
Anavex Life Sciences
Aug 9, 2023
Reiterated: Buy
Price Target: $40
Current: $2.66
Upside: n/a
Denali Therapeutics
Aug 9, 2023
Reiterated: Buy
Price Target: $54
Current: $21.40
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $15
Current: $10.62
Upside: n/a
Aug 3, 2023
Reiterated: Buy
Price Target: $61
Current: $8.56
Upside: n/a
Apr 29, 2019
Reiterated: Buy
Price Target: $10
Current: $17.18
Upside: n/a
Apr 23, 2019
Rated: Buy
Price Target: $5
Current: $2.97
Upside: n/a
Apr 4, 2019
Reiterated: Buy
Price Target: $3
Current: $0.7051
Upside: n/a
Apr 1, 2019
Downgraded: Hold
Price Target: n/a
Current: $3.35
Upside: n/a
Apr 1, 2019
Reiterated: Buy
Price Target: $6
Current: $0.239
Upside: n/a
Mar 28, 2019
Reiterated: Buy
Price Target: $9
Current: $1.03
Upside: n/a
Mar 20, 2019
Rated: Buy
Price Target: $4 → $40
Current: $6.57
Upside: n/a
Mar 14, 2019
Reiterated: Buy
Price Target: 1,332p → 1,327p
Current: 444p
Upside: n/a
Mar 20, 2018
Rated: Buy
Price Target: $34
Current: $0.3223
Upside: n/a
Mar 13, 2018
Rated: Buy
Price Target: $20
Current: $8.24
Upside: n/a
Mar 9, 2018
Rated: Buy
Price Target: $9
Current: $2.10
Upside: n/a
Aug 8, 2017
Rated: Buy
Price Target: $8
Current: $8.29
Upside: n/a
Jun 13, 2017
Rated: Buy
Price Target: n/a
Current: $0.00001
Upside: n/a
Jun 7, 2017
Rated: Buy
Price Target: n/a
Current: $0.006
Upside: n/a
May 17, 2017
Rated: Buy
Price Target: n/a
Current: $2.58
Upside: n/a
Apr 24, 2017
Rated: Buy
Price Target: n/a
Current: $0.075
Upside: n/a
Mar 2, 2016
Initiated Coverage: Buy
Price Target: $18
Current: $0.0003
Upside: n/a